Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1.-68. (Canceled).

69. (Currently amended) A method of treating~~, or preventing, or delaying progression of~~ prostate cancer comprising:

providing an antibody or antigen binding portion thereof which competes for binding to prostate specific membrane antigen (PSMA) with a monoclonal antibody selected from the group consisting of an E99, a J415, a J533, and a J591 monoclonal antibody; and

administering the antibody or antigen binding portion thereof to a subject under conditions effective to treat~~, or prevent, or delay the progression of~~ prostate cancer.

70. (Currently amended) The method according to claim 69, wherein the prostate cancer is metastatic prostate cancer.

71. (Previously presented) The method according to claim 70, wherein the metastatic prostate cancer involves a bone marrow or a lymph node metastasis.

72. (Currently amended) [[A]] The method according to claim 69, wherein the administering is carried out parenterally.

73. (Currently amended) [[A]] The method according to claim [[72]] 69, wherein the administering is carried out intravenously.

74. (Currently amended) [[A]] The method according to claim 69, wherein the administering is carried out by intracavitary instillation.

75. (Currently amended) [[A]] The method according to claim 69, wherein the administering is carried out rectally.

76. (Currently amended) [[A]] The method according to claim 69, wherein the antibody or antigen binding portion thereof is administered following a prostatectomy.

77. (Currently amended) [[A]] The method according to claim 69, wherein the antibody or antigen binding portion binds live cells.

78. (Currently amended) [[A]] The method according to claim 69, wherein the antibody is selected from the group consisting of a monoclonal antibody and a polyclonal antibody.

79. (Currently amended) [[A]] The method according to claim 78, wherein the antibody is a monoclonal antibody selected from the group consisting of an E99, a J415, a J533, and a J591 monoclonal antibody.

80. (Currently amended) [[A]] The method according to claim 78, wherein the antibody is a monoclonal antibody produced by a hybridoma having an ATCC Accession Number selected from the group consisting of HB-12101, HB-12109, HB-12127, and HB-12126.

81-123. (Canceled)

124. (Currently amended) A method of treating~~, or preventing or delaying progression of~~ prostate cancer comprising:

providing an antibody or antigen binding portion thereof which competes for binding to prostate specific membrane antigen with a monoclonal antibody selected from the group consisting of an E99, a J415, a J533, and a J591 monoclonal antibody, wherein the antibody is labeled with the radiolabel ^{90}Y; and

administering the antibody or antigen binding portion thereof to a subject under conditions effective to treat ~~or prevent or delay the progression of~~ prostate cancer.

125. (Currently amended) A method of treating~~, or preventing, or delaying progression of~~ prostate cancer comprising:

providing an antibody or antigen binding portion thereof which competes for binding to prostate specific membrane antigen with a monoclonal antibody selected from the group consisting of an E99, a J415, a J533, and a J591 monoclonal antibody, wherein the antibody is labeled with a radiolabel, and wherein the radiolabel is a beta- or gamma-emitter; and

administering the antibody or antigen binding portion thereof to a subject under conditions effective to treat~~, or prevent or delay the progression of~~ prostate cancer.

126. (Currently amended) A method of treating~~, or preventing, or delaying progression of~~ prostate cancer comprising:

providing an antibody or antigen binding portion thereof which competes for binding to prostate specific membrane antigen with a monoclonal antibody selected from the group consisting of an E99, a J415, a J533, and a J591 monoclonal antibody, wherein the antibody is bound to a cytotoxic drug of bacterial origin; and

administering the antibody or antigen binding portion thereof to a subject under conditions effective to treat~~, or prevent, or delay the progression of~~ prostate cancer.

127. (Currently amended) A method of treating~~, or preventing or delaying progression of~~ prostate cancer comprising:

providing an antibody or antigen binding portion thereof which competes for binding to

prostate specific membrane antigen with a monoclonal antibody selected from the group consisting of an E99, a J415, a J533, and a J591 monoclonal antibody, wherein the antibody is bound to a cytotoxic drug of plant origin; and

administering the antibody or antigen binding portion thereof to a subject under conditions effective to treat~~, or prevent or delay the progression of~~ prostate cancer.

128. (Canceled)

129. (Currently amended) [[A]] The method according to claim 69, wherein the antibody or antigen binding portion thereof competes for binding to prostate specific membrane antigen with the J591 monoclonal antibody [[J591]].

130. (Currently amended) [[A]] The method according to claim 69, wherein the antibody or antigen binding portion thereof competes for binding to prostate specific membrane antigen with the J415 monoclonal antibody [[J415]].

131.–135. (Canceled).

136. (Currently amended) [[A]] The method according to claim 69, 125, 126 or 127, wherein the antibody is a monoclonal antibody or the antigen binding portion thereof is derived from a monoclonal antibody.

137. (Currently amended) [[A]] The method according to claim 69, 125, 126 or 127, wherein the antibody or antigen binding portion thereof is internalized with the prostate specific membrane antigen.

138. (Currently amended) [[A]] The method according to claim 69, 125, 126 or 127, wherein the ~~antibody or~~ antigen binding portion ~~thereof~~ is selected from the group consisting of

a Fab fragment, a [[F(ab')2]] F(ab')$_2$ fragment, and a Fv fragment.

139. (Currently amended) [[A]] The method according to claim 69, wherein the antibody or antigen binding portion thereof ~~further~~ comprises a cytotoxic drug.

140. (Currently amended) [[A]] The method according to claim 139, wherein the cytotoxic drug is selected from the group consisting of a therapeutic drug, a compound emitting radiation, a molecule ~~molecules~~ of plant, fungal, or bacterial origin, a biological protein ~~proteins~~, and a mixture ~~mixtures~~ thereof.

141. (Currently amended) [[A]] The method according to claim 140, wherein the cytotoxic drug is a compound emitting radiation.

142. (Currently amended) [[A]] The method according to claim 141, wherein the compound emitting radiation is an alpha-emitter.

143. (Currently amended) [[A]] The method according to claim 142, wherein the alpha-emitter is selected from the group consisting of ^{212}Bi, ^{213}Bi, and ^{211}At.

144. (Currently amended) [[A]] The method according to claim 141, wherein the compound emitting radiation is a beta-emitter.

145. (Currently amended) [[A]] The method according to claim 144, wherein the beta-emitter is ^{186}Re.

146. (Currently amended) [[A]] The method according to claim 144, wherein the beta-emitter is ^{90}Y.

147. (Currently amended) [[A]] The method according to claim 141, wherein the compound emitting radiation is a gamma-emitter.

148. (Currently amended) [[A]] The method according to claim 147, wherein the gamma-emitter is ^{131}I.

149. (Currently amended) [[A]] The method according to claim 141, wherein the compound emitting radiation is a beta- and gamma-emitter.

150. (Currently amended) [[A]] The method according to claim 140, wherein the cytotoxic drug is a molecule of bacterial origin.

151. (Currently amended) [[A]] The method according to claim 140, wherein the cytotoxic drug is a molecule of plant origin.

152. (Currently amended) [[A]] The method according to claim 140, wherein the cytotoxic drug is a biological protein.

153. (Currently amended) [[A]] The method according to claim 69, wherein the antibody or antigen binding portion thereof ~~further~~ comprises a label.

154. (Currently amended) [[A]] The method according to claim 153, wherein the label is selected from the group consisting of a biologically-active enzyme label[[,]] and a radiolabel.

155. (Currently amended) [[A]] The method according to claim 154, wherein the label is a radiolabel selected from the group consisting of ^{111}In, [[^{99}mTc]] ^{99m}Tc, ^{32}P, ^{125}I, ^{131}I, ^{14}C, ^{3}H and ^{188}Rh.

156. (Currently amended) [[A]] The method according to claim 69, 125, 126 or 127, wherein the antibody or antigen binding portion thereof is effective to initiate an endogenous host immune function.

157. (Currently amended) [[A]] The method according to claim 156, wherein the endogenous host immune function is complement-mediated cellular cytotoxicity.

158. (Currently amended) [[A]] The method according to claim 156, wherein the endogenous host immune function is antibody-dependent cellular cytotoxicity.

159. (Currently amended) [[A]] The method according to claim 69, 125, 126 or 127, wherein the antibody or antigen binding portion thereof is in a composition further comprising a pharmaceutically acceptable carrier, excipient, or stabilizer.

160. (Previously presented) The method according to claim 69, 125, 126 or 127 wherein the antibody or antigen binding portion thereof is administered in conjunction with a second therapeutic modality.

161. (Previously presented) The method according to claim 160, wherein the second therapeutic modality is selected from the group consisting of surgery, radiation, chemotherapy, immunotherapy and hormone replacement.

162. (Previously presented) The method according to claim 161, wherein the hormone replacement comprises treatment with estrogen or an anti-androgen agent.

163. (Previously presented) The method according to claim 162, wherein the anti-androgen agent is an agent which blocks or inhibits the effects of testosterone.

164. (Currently amended) The method according to claim 126, wherein the prostate cancer is metastatic prostate cancer.

165. (Previously presented) The method according to claim 164, wherein the metastatic prostate cancer involves a bone marrow or a lymph node metastasis.

166. (Currently amended) [[A]] The method according to claim 126, wherein the administering is carried out parenterally.

167. (Currently amended) [[A]] The method according to claim [[166]] 126, wherein the administering is carried out intravenously.

168. (Currently amended) [[A]] The method according to claim 126, wherein the administering is carried out by intracavitary instillation.

169. (Currently amended) [[A]] The method according to claim 126, wherein the administering is carried out rectally.

170. (Currently amended) [[A]] The method according to claim 126, wherein the antibody or antigen binding portion thereof is administered following a prostatectomy.

171. (Currently amended) [[A]] The method according to claim 126, wherein the antibody or antigen binding portion binds live cells.

172. (Currently amended) [[A]] The method according to claim 126, wherein the antibody is a monoclonal antibody selected from the group consisting of an E99, a J415, a J533, and a J591 monoclonal antibody.

173. (Currently amended) [[A]] The method according to claim 126, wherein the antibody is a monoclonal antibody produced by a hybridoma having an ATCC Accession Number selected from the group consisting of HB-12101, HB-12109, HB-12127, and HB-12126.

174 –185. (Canceled)

186. (Currently amended) [[A]] The method according to claim 126, wherein the antibody or antigen binding portion thereof competes for binding to prostate specific membrane antigen with the J591 monoclonal antibody [[J591]].

187-189. (Canceled)

190. (New) The method according to claim 69, 124, 125, 126, or 127, wherein the method of treating prostate cancer is a method that prevents or delays the progression of prostate cancer.